A Libtayo combo fails to beat Keytruda in first-line melanoma.
ApexOnco Front Page
Recent articles
Golcadomide and iberdomide are set to feature at EHA.
MK-6837 has been discontinued, the company discloses.
A US advisory committee votes against camizestrant, but does endorse a new use for Truqap.
Dispatch Bio’s virus therapy DV-10 enters phase 1.
The company discontinues the Lag3 project in lung cancer.
The QCS assay for TROP2 is being implemented more broadly, at the cost of further readout delays.
Unlike the US FDA, the CHMP doesn't recommend approval for pre-chemo prostate cancer.
